Author

Miao Pang

Nanjing University of Chinese Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Chong QiniD· 1 shared Dan TengiD· 1 shared Dan Wang· 1 shared Guizhen Zhou· 1 shared J Q XuiD· 1 shared Kaixian CheniD· 1 shared M W HuangiD· 1 shared Mingliang WangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chong QinORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Functional orthogonality of WRN inhibitor resistance enables alternating therapy and mutation-tolerant inhibitor design in MSI-H cancers

Guizhen Zhou, Dan Teng, Dan Wang, Miao Pang, Zisheng Fan, Yuyan Tao, Shuai Chen, Xiaomin Yang, M W Huang, Panpan Shao, Yun Liu, Rongrong Cui, Zhiyin Xie, Yi Zhou, Zhiming Ge, , Mingyue Zheng

This study shows that resistance to different WRN inhibitors in MSI-H cancers creates orthogonal vulnerabilities, enabling alternating therapy and mutation-tolerant inhibitor design.

bioRxiv · Jun 12, 2026 · PreprintCancer Biology